Elixir Medical Corporation

Print Article

PRESS RELEASE

Elixir Medical Announces Schedule of Programs for TCT 2015

First Live Case Transmission of the Fully Bioresorbable DESolve® Cx Novolimus Eluting Coronary Scaffold System

Sunnyvale, CAOctober 7, 2015—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will  stream the first live transmission case demonstration of its breakthrough DESolve® Cx Novolimus Eluting Bioresorbable Coronary Scaffold System at the 27th annual Transcatheter Cardiovascular Technologies (TCT) Conference in San Francisco, California, on Monday, October 12. The Elixir Satellite Symposium is scheduled for Wednesday, October 14.

Elixir will also present 3-year clinical and imaging results for its DESolve® Nx Novolimus Eluting Bioresorbable Coronary Scaffold System during the scientific conference.  Following are the details of Elixir Medical’s programs and activities at TCT in Pacific Time (PT):

Monday, October 12:

8:45 AM, Moscone South, Esplanade Level, Main Arena
DESolve®Cx Live Case

3:26 – 3:33 PM, Moscone West, 3rd Floor, Room 3001 - 3005
Device and Clinical Program Highlights: DESyne BD

Tuesday, October 13:

3:45 – 4:00 PM, Moscone West, 2nd Floor, Room 2010
Prospective, multicenter evaluation of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold – Imaging outcomes and 3-year clinical and imaging results

Poster Sessions: 4- 6 PM, Poster Hall, Moscone West

Poster 2083: Multi-Center, Randomized Evaluation of the Elixir DESyne® Novolimus Eluting Coronary Stent System with Biodegradable Polymer Compared to a Zotarolimus-Eluting Coronary Stent System: 4-Year Results from the EXCELLA BD Study ®

Poster 2183: Multi-Center, Post-marketing Evaluation of the Elixir DESyne® Novolimus Eluting Coronary Stent System: 1-Year Results from the EXCELLA PMCF Study

Poster 2178: Multi-Center, Post-marketing Evaluation of the Elixir DESolve® Novolimus ElutingBioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study

Poster 4191: Successful revascularization of three vessel coronary disease involving a very challenging chronic total occlusion lesion with multiple DESolve

Wednesday, October 14:

1 – 2 pm, Moscone South, Lower Level, Exhibit Hall, Presentation Theater 3
Elixir Satellite Symposium: Transforming PCI with the DESolve Novolimus Eluting Scaffold Platforms

Chairs

Faculty

Space is limited: Please register in advance at www.tctconference.com/satelliteprograms

7:17 – 7:24 PM Ballroom Level, Continental Ballroom 1-4
Thin struts with self-correcting property (DESolve)

 

Elixir Medical will have a booth at TCT:  Booth 1533, Exhibit Hall. The booth will be open Monday, October 12 through Wednesday, October 14 from 9 AM to 5 PM.

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com

 

***

 

Contact:

Donna Collins, Elixir Medical

Ph: (408) 636-2060